Allogene Therapeutics Inc [ALLO] stock is trading at $1.11, down -4.31%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALLO shares have gain 16.50% over the last week, with a monthly amount drifted -30.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on May 14, 2025, when Citizens JMP downgraded its rating to a Mkt Perform. Previously, Citizens JMP upgraded its rating to Mkt Outperform on March 14, 2025, and kept the price target unchanged to $5. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $11 on May 31, 2024. JMP Securities downgraded its rating to a Mkt Perform. Guggenheim downgraded its rating to Neutral for this stock on January 05, 2024. In a note dated December 08, 2023, Citigroup initiated an Buy rating and provided a target price of $7 on this stock.
Allogene Therapeutics Inc [ALLO] stock has fluctuated between $0.86 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.11 at the most recent close of the market. An investor can expect a potential return of 2512.61% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
Allogene Therapeutics Inc [NASDAQ:ALLO] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 12222.09%, Pretax Profit Margin comes in at 11449.09%, and Net Profit Margin reading is 11469.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.56 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Allogene Therapeutics Inc’s Current Ratio is 9.71. In addition, the Quick Ratio stands at 9.71 and the Cash Ratio stands at 1.41.
Transactions by insiders
Recent insider trading involved Yoshiyama Annie, SVP, Finance, that happened on Apr 21 ’25 when 9601.0 shares were sold. Officer, Yoshiyama Annie completed a deal on Apr 21 ’25 to buy 9601.0 shares. Meanwhile, President and CEO Chang David D sold 46668.0 shares on Mar 14 ’25.
